Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $45.33.

Several research analysts have recently issued reports on ARWR shares. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and set a $62.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, October 11th.

Arrowhead Pharmaceuticals Trading Up 0.9 %

NASDAQ:ARWR opened at $20.10 on Monday. The company’s 50 day moving average is $21.09 and its two-hundred day moving average is $23.71. The company has a market cap of $2.50 billion, a PE ratio of -4.73 and a beta of 0.95. Arrowhead Pharmaceuticals has a twelve month low of $17.05 and a twelve month high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). The firm’s revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.96) earnings per share. As a group, analysts expect that Arrowhead Pharmaceuticals will post -4.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Fifth Third Bancorp boosted its position in Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 354 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $52,000. Headlands Technologies LLC grew its stake in Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 2,386 shares during the period. Meeder Asset Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.